Alzheimer’s disease and cannabinoids
Alzheimer’s disease (AD) is currently the most common cause of dementia, constituting 65% of the registered cases, and affects people from the age of 60 on average. This neurodegenerative disease is irreversible, and leads more or less quickly, to the loss of cognitive abilities of the person who suffers from it.
The clinical features of AD include memory loss, especially recent events in the earlier stages of the process, as well as changes in cognitive abilities that interfere with mood, reasoning, and verbal expression. The course of the disease is insidious, and it is estimated that some AD patients can survive up to 20 years after being diagnosed, although the median survival ranges from 5 to 10 years. Age is the main risk factor so that from the age of 60, the probability of suffering from this disease doubles with every 5 years. For this reason, EA appears as one of the biggest current health problems, and that will cause an increasing socio-economic impact in the coming decades. Buy CBD cigarettes – regular
In addition to affecting memory, patients with Alzheimer’s frequently have verbal language problems and cannot express themselves correctly, vocabulary is impoverished. There is also frequent disorientation, behavioral changes, insomnia, night agitation, biorhythm disturbances, in short, and loss of appetite.
The brain is breaking down as a result of the evolution of the disease, which can develop with more or less variable speed, depending on each individual, although there are valuable genetic and hereditary factors that determine its development.
Today the causes of the disease are unknown, but in recent years the understanding of the molecular mechanisms that are involved in the development of the disease has improved.
Basically we know that the accumulation of a protein called beta-amyloid, in brain tissue, ends up forming plaques and tangles called neurofibrillary, which lead to situations of neuroinflammation and toxicity in the brain tissue, which determine the loss of brain volume due to neuronal death. This evidently determines the loss of abilities of the patient, which is usually initially expressed with a memory impairment, which from a certain age is a data that is difficult to evaluate, although there are different tests and questionnaires that can guide the Alzheimer’s diagnosis. Buy CBD cigarettes – menthol online
Currently, the therapeutic arsenal available for the treatment of AD remains very limited. Among the most widely used drugs, today are acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine), which is the enzyme responsible for the degradation of the neurotransmitter acetylcholine. Its use is justified by the observation that, in general terms, the cholinergic deficit in the brain of patients with AD may explain some of the cognitive, functional, and behavioral alterations of these patients. However, we must consider other lines of therapeutic development that address different aspects of the disease and in which the use of agents capable of modulating endocannabinoid tone could be important. These include the use of antiglutamatergic agents,
It is important to highlight that, although the use of cannabinoids could be valued from the outset as counterproductive for the treatment of AD, due to its psychoactive and memory effects -remember that the use of THC affects immediate memory-, there are other aspects of the symptomatology of the disease that could have beneficial effects. Such is the case of night agitation, on which THC and CBD seem to exert a beneficial effect. Also, the stimulant effect of appetite and antiemetic can be useful for the treatment of these patients.
There are studies that indicate that the endocannabinoid system is directly involved in the processes that take place in the brain affected by Alzheimer’s disease. Buy CBD flower online
It is here where we can reflect on the use of phytocannabinoids for the treatment of the pathology presented by these patients.
We have two situations in which cannabinoids are effective, which are neuroinflammation and oxidative stress that lead to neurotoxicity and neuronal death in the medium and long term.
In addition, we must remember the low toxicity of phytocannabinoids, which involves safe handling without the appearance of side effects that could put the patient at risk of life or generate uncomfortable situations for him. Remember that acute cannabis poisoning has never been a proven direct cause of death in any deceased.
Basically, studies have focused on the application of Cannabidiol (CBD) for medium and long-term treatment, since it has very interesting properties to treat symptoms and counteract the neuroinflammation situation that patients present.
We have talked about neuroinflammation, and CBD is an effective anti-inflammatory also at the CNS level, where the accumulation of neurofibrillary tangles and plaques constitutes one of the causes of the associated inflammatory processes that generate a multitude of molecules that are toxic to neurons. These molecules called free radicals are toxic to cells, and constitute the so-called oxidative stress. Being able to eliminate or counteract these radicals is crucial for the balance of cells and tissues, and CBD also gives us the antioxidant effect we need in this situation. Buy CBD prerolls online
Therefore, the use of CBD in the treatment of Alzheimer’s disease is being studied, but we do not currently have results in the medium and long term, which could determine the efficacy of its use, which is also determined by the phase of the disease in which treatment begins.
Many patients have anxious symptoms, and here the anxiolytic effect of cannabinoids is useful to try to control anxiety, and it is also useful to induce sleep, at nighttime doses, in patients with mild sleep disturbance. On many occasions it is necessary to associate with treatment with THC, to treat insomnia or night agitation that some patients present.
CBD also provides in many cases an improvement in cognitive aspects, which are valuable and confirmed by family members or caregivers. There are patients who improve verbal language, better orientation, better communication with the environment, more emotional stability, within reasonable expectations. And always in relation to the phase of the disease and the idiosyncrasy of each patient. Buy marijuana online
We can expect, therefore, from treatment with cannabinoids, short-term effects, by acting on the symptoms presented by patients, but it would also be possible to act in the medium and long term on the development of the disease, with the intention of slowing down or stopping the development of the disease. Current studies and future clinical trials will determine that cannabinoids become part of the therapeutic arsenal for these patients.